SG10202108219QA - Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease - Google Patents

Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease

Info

Publication number
SG10202108219QA
SG10202108219QA SG10202108219QA SG10202108219QA SG10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA SG 10202108219Q A SG10202108219Q A SG 10202108219QA
Authority
SG
Singapore
Prior art keywords
disease
prophylactic
therapeutic agent
inflammatory disease
infectious disease
Prior art date
Application number
SG10202108219QA
Inventor
Kazuo Suzuki
Yosuke Kameoka
Yoshio Yamakawa
Fukuko Kishi
Osamu Suzuki
Minako Koura
Junichiro Matsuda
Original Assignee
A Clip Institute Co
National Institutes Of Biomedical Innovation Health And Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Clip Institute Co, National Institutes Of Biomedical Innovation Health And Nutrition filed Critical A Clip Institute Co
Publication of SG10202108219QA publication Critical patent/SG10202108219QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0337Animal models for infectious diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0368Animal model for inflammation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775Apolipopeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
SG10202108219QA 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease SG10202108219QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017013486 2017-01-27

Publications (1)

Publication Number Publication Date
SG10202108219QA true SG10202108219QA (en) 2021-08-30

Family

ID=62978497

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202108219QA SG10202108219QA (en) 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease
SG11201906968YA SG11201906968YA (en) 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201906968YA SG11201906968YA (en) 2017-01-27 2018-01-26 Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease

Country Status (9)

Country Link
US (2) US20190367600A1 (en)
EP (2) EP3581204A4 (en)
JP (1) JP7126658B2 (en)
KR (1) KR102581165B1 (en)
CN (1) CN110267680B (en)
AU (1) AU2018213716A1 (en)
CA (1) CA3051826A1 (en)
SG (2) SG10202108219QA (en)
WO (1) WO2018139608A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020376350A1 (en) * 2019-10-30 2022-05-26 National University Corporation Okayama University Prophylactic and/or therapeutic agent for inflammatory pulmonary disease
WO2024004580A1 (en) * 2022-06-30 2024-01-04 国立大学法人千葉大学 Method for testing disease progression toward vasculitis or testing risk of covid-19 becoming severe, testing kit, companion diagnostic agent, and testing marker

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US164290A (en) 1875-06-08 Improvement in bedsteads
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
JP2000014383A (en) 1998-07-03 2000-01-18 Igaku Seibutsugaku Kenkyusho:Kk Humanized antibody
FR2801407B1 (en) 1999-11-22 2002-04-12 Roger Felix Sejalon CONTINUOUSLY TRACABLE INVIOLABLE LABEL BRACELET
JP2004081199A (en) 2002-06-25 2004-03-18 Sekisui Chem Co Ltd Method for producing recombinant antibody
US9028822B2 (en) * 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP3965147B2 (en) 2003-11-04 2007-08-29 ヤンマー株式会社 Claw shaft attachment / detachment structure of rotary tiller
EP2306192B1 (en) * 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2009044723A1 (en) * 2007-10-04 2009-04-09 Biomarker Science Co., Ltd. Method for prediction of effect of interferon therapy and kit for prediction
GB0720976D0 (en) * 2007-10-26 2007-12-05 Medical Res Council Treatment of inflammatory disease
US8225183B2 (en) 2008-09-30 2012-07-17 Lsi Corporation Methods and apparatus for selective data retention decoding in a hard disk drive
US9435813B2 (en) * 2010-05-11 2016-09-06 The General Hospital Corporation Biomarkers of hemorrhagic shock
US9244079B2 (en) 2010-09-22 2016-01-26 National University Corporation Chiba University Testing method and testing reagent for angiitis
US10196457B2 (en) * 2011-12-19 2019-02-05 National University Corporation Chiba University Artificial immunoglobulin fragment composition
US10208131B2 (en) 2011-12-19 2019-02-19 National University Corporation Chiba University Artificially produced polyclonal immunoglobulin preparation
US20160245815A1 (en) * 2013-10-01 2016-08-25 Toray Industries, Inc. Method for detecting pancreatic tumor, antibodies, and kit for the detection of pancreatic tumor
JP5685672B1 (en) 2014-07-10 2015-03-18 株式会社山岡製作所 Resin molding method
DK3252474T3 (en) * 2015-01-26 2020-11-09 Toray Industries PROCEDURE AND KIT FOR DETECTING BILEWAY CANCER
JP6670129B2 (en) 2015-02-27 2020-03-18 国立大学法人千葉大学 Artificial immunoglobulin fragment composition
DK3267197T3 (en) * 2015-03-02 2020-10-12 Toray Industries METHOD AND KIT FOR THE DETECTION OF PANCREATIC DYSFUNCTION
US9895848B2 (en) 2015-04-22 2018-02-20 The Boeing Company Systems and tooling for manufacturing composite parts and related methods
JP6453199B2 (en) 2015-10-16 2019-01-16 光洋機械工業株式会社 Centerless grinding machine

Also Published As

Publication number Publication date
CA3051826A1 (en) 2018-08-02
US20220213180A1 (en) 2022-07-07
KR20190108152A (en) 2019-09-23
EP3581204A4 (en) 2020-12-16
KR102581165B1 (en) 2023-09-21
WO2018139608A1 (en) 2018-08-02
JPWO2018139608A1 (en) 2020-01-09
JP7126658B2 (en) 2022-08-29
US20190367600A1 (en) 2019-12-05
EP3581204A1 (en) 2019-12-18
EP4317431A3 (en) 2024-05-22
AU2018213716A1 (en) 2019-08-15
SG11201906968YA (en) 2019-08-27
EP4317431A2 (en) 2024-02-07
CN110267680B (en) 2023-12-19
CN110267680A (en) 2019-09-20

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
EP3878348C0 (en) Medical devices and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
IL273959A (en) Methods and compositions for the treatment of rare diseases
EP3503903A4 (en) Ascaroside treatment of autoimmune and inflammatory diseases
HK1251265A1 (en) Diagnosis and treatment of infectious disease
IL247368A0 (en) Diagnostic and therapeutic uses of exosomes
ZA201906169B (en) Synthekine compositions and methods of use
SG11201912185XA (en) Three dimensional tissue compositions and methods of use
IL285928A (en) Fulvestrant formulations and methods of their use
FI3380525T3 (en) Pharmaceutical formulations and methods of use thereof
EP3473259A4 (en) Trophic factor release agent and inflammatory disease treatment agent
SG10202108219QA (en) Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease
IL274433A (en) Fulvestrant formulations and methods of their use
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
GB2615479B (en) Therapeutic and prophylactic use of microoganisms
SG11201704430SA (en) Preventive and/or therapeutic agent of immune disease
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
EP3648777A4 (en) Exosomes and methods of use thereof
EP3536382A4 (en) Prophylactic or therapeutic agent for inflammatory skin disease
IL272604A (en) Methods and compositions for treatment of inflammatory bowel disease
EP3272349A4 (en) Therapeutic and/or prophylactic agent for lewy body diseases
EP3616687C0 (en) Preparation for the treatment and/or prophylaxis of inflammatory infectious diseases
SG11202002316PA (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
GB201718856D0 (en) Medicinal compositions for the treatment of inflammatory conditions and autoimmune diseases